معرفی
Anne M Filppula is a researcher at the University of Helsinki's Faculty of Medicine, Department of Clinical Pharmacology. She holds a PhD in Medicine from the University of Helsinki (awarded December 16, 2014) and an MScPharm from Uppsala University. With over 30 publications spanning from 2010 to 2024, her research focuses on clinical pharmacology, pharmacogenetics, and drug metabolism.
Her educational background includes:
- PhD in Medicine, University of Helsinki (2014)
- MScPharm/MPharmSc in Pharmacy, Uppsala University
Filppula's research interests center on drug metabolism mechanisms, particularly cytochrome P450 enzymes, pharmacogenetics, and personalized medicine approaches. Her work frequently examines drug-drug interactions, enzyme inhibition, and the clinical implications of genetic variations in drug response. She has made significant contributions to understanding CYP enzyme function and its impact on drug efficacy and safety.
Her recent publications demonstrate a consistent focus on cytochrome P450 enzymes, drug metabolism pathways, and pharmacogenetic factors affecting drug response. The research spans from fundamental enzyme kinetics to clinical applications in personalized medicine, with particular attention to drugs like hydroxychloroquine, statins, and antiplatelet agents.
Among her notable achievements are:
- Award for best oral presentation at NORPM 2018
- Best Thesis Award 2014 from the Finnish Society of Clinical Pharmacology
- Biomedicum Helsinki Foundation Young Scientist Prize (2013)
- FPDP Best Poster Prize (2013)
- FPDP-C Best Poster Prize (2014)
Filppula actively contributes to her field through peer review activities for journals including Basic & Clinical Pharmacology & Toxicology, European Journal of Clinical Pharmacology, and Xenobiotica. She has participated in numerous conferences, including the First Nordic Conference on Personalized Medicine (2018) where she presented on protein kinase inhibitors as time-dependent inhibitors of CYP3A4. Her collaborative work spans multiple research projects including TransporterPGx (ERC Starting Grant), Mechanism-Based Inactivation of Cytochrome P450 (Academy of Finland project), and Individual variability in drug response (IndiViDrug).
Her research group focuses on understanding the molecular mechanisms underlying drug response variability, with particular emphasis on pharmacogenetic factors and drug metabolism pathways. The team employs both in vitro and clinical approaches to translate basic science findings into clinical practice for improved drug therapy.
